This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Miwa, G. T. Search for Related Content PubMed PubMed Citation Articles by Miwa, G. T. Social Bookmarking                         What's this?

Goals, Design, Timing, and Future Opportunities for Nonclinical Drug Metabolism Studies

Glaxo Research Institute, Research Triangle Park, North Carolina 27009

The nonclinical ADME (adsorption, distribution, metabolism, and excretion) studies employed during drug development are dependent on the regulatory expectations and the changing development focus from nonclinical to clinical issues. These evolving issues necessitate that the development goals for ADME studies also change during the development process. The rationale for these goal changes and their impact on the timing and design of the ADME studies are discussed in the context of drug development at Glaxo Inc. The progress in the technology and knowledge in drug metabolism and in biology provide new opportunities for pharmaceutical companies in predicting drug toxicities relevant to humans. Two case examples are discussed to illustrate this opportunity.

Key Words: Drug development • metabolism

• Boyd MR and Burka LT (1978). In vivo studies on the relationship between target organ alkylation and the pulmonary toxicity of a chemically reactive metabolite of 4-ipomeanol. J. Pharmacol. Exp. Ther. 207(3): 687-697.[Abstract/Free Full Text]
• Boyd MR, Burka LT, Harris TM, and Wilson BJ (1974). Lung-toxic furanoterpenoids produced by sweet potatoes (Ipomoea batatas) following microbial infection. Biochim. Biophys. Acta 337(2): 184-195.[Medline] [Order article via Infotrieve]
• Devereux TR, Jones KG, Bend JR, Fouts JR, Statham CN, and Boyd MR (1981). In vitro activation of the pulmonary toxin, 4-ipomeanol, in noncilicated bronchiolar epithelial (Clara) and alveolar Type II cells isolated from rabbit. J. Pharrn. Exp. Ther. 220: 223-227.
• Guengerich FP (1989). Polymorphism ofcytochromc P-450 in humans. TIPS 10: 107-109.[Medline] [Order article via Infotrieve]
• Guengerich FP (1992). Human cytochrome P-450 enzymes. Life Sci. 50: 1471-1478.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Guengerich FP and Kim D-H. (1990). In vitro inhibition of dihydropyridine oxidation and aflatoxin B1 activation in human liver microsomes by naringenin and other flavonoids. Carcinogenesis 11: 2275-2279.[Abstract/Free Full Text]
• Kinsolving CR and Munro NL (1975). The objective and timing of drug disposition studies, Appendix V. A comparison of the bioavailability of three dosage forms of terfenadine. Drug Metab. Rev. 4(2): 285-290.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Peck CC, Temple R., and Collins JM (1993). Understanding consequences of concurrent therapies. JAMA 269: 1550-1552.[Abstract/Free Full Text]
• Serabjit-Singh CJ, Wolf CR Philpot RM, and Plop-per CG (1980). Cytochrome P-450: Localization in the rabbit lung. Science 207: 1469-1470.[Abstract/Free Full Text]
• Smith PB, Tiano HF, Philpot RM, Nesnow S., and Langenbach RJ (1994). Cytotoxicity of 4-ipomeanal (4-IPO) in C3H/10T cells expressing pulmonary cytochrome P-450 4B1. FASEB J. 8: A1249.
• Vocci F. and Farber T. (1988). Extrapolation of animal toxicity data to man. Regul. Toxicol. Pharmacol. 8: 389-398.[CrossRef][Web of Science][Medline] [Order article via Infotrieve]
• Woosley RL, Chen Y., Freiman JP, and Gillis RA (1993). Mechanism of the cardiotoxic actions of terfenadine. JAMA 269: 1532-1536.[Abstract/Free Full Text]

Toxicologic Pathology, Vol. 23, No. 2, 131-135 (1995)
DOI: 10.1177/019262339502300205


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				G. N. Kumar, C. Sproul, L. Poppe, S. Turner, M. Gohdes, H. Ghoborah, D. Padhi, and L. Roskos METABOLISM AND DISPOSITION OF CALCIMIMETIC AGENT CINACALCET HCL IN HUMANS AND ANIMAL MODELS Drug Metab. Dispos., December 1, 2004; 32(12): 1491 - 1500. [Abstract] [Full Text] [PDF]

				F. Gao, D. L. Johnson, S. Ekins, J. Janiszewski, K. G. Kelly, R. D. Meyer, and M. West Optimizing Higher Throughput Methods to Assess Drug-Drug Interactions for CYP1A2, CYP2C9, CYP2C19, CYP2D6, rCYP2D6, and CYP3A4 In Vitro Using a Single Point IC50 J Biomol Screen, August 1, 2002; 7(4): 373 - 382. [Abstract] [PDF]

This Article Abstract Free Full Text (Free PDF) Free Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Miwa, G. T. Search for Related Content PubMed PubMed Citation Articles by Miwa, G. T. Social Bookmarking                         What's this?